Influenza clinical trials

Explore recruiting influenza clinical trials.

Recruiting influenza studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Influenza trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years

France, Finland, Belgium, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase IV study to investigate the immunogenicity of the Seqirus licensed MF59 adjuvanted zoonotic influenza vaccine (H5N8) in adults previously vaccinated in 2009 with the Matrix M adjuvanted virosomal influenza (H5N1) vaccine compared to H5 naïve adults.

Norway

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Romania, Bulgaria, Finland, Spain, Poland, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Optimizing the time of day of influenza vaccine administration in adults aged 60-85 years: A randomized controlled trial

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2

France

Therapeutic use (Phase IV) EU CTIS Study details

Influenza trials by city

Influenza in Toronto Influenza in Vancouver Influenza in Montreal Influenza in Calgary Influenza in Edmonton Influenza in Ottawa Influenza in Winnipeg Influenza in Quebec City Influenza in Hamilton Influenza in Kitchener Influenza in London Influenza in Halifax Influenza in New York Influenza in Los Angeles Influenza in Chicago Influenza in Houston

Influenza clinical trials

Recruiting influenza studies right now

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

Dime La VerDAD: Verify, Debunk, and Disseminate

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care

Also recruiting in Europe

Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years

A phase IV study to investigate the immunogenicity of the Seqirus licensed MF59 adjuvanted zoonotic influenza vaccine (H5N8) in adults previously vaccinated in 2009 with the Matrix M adjuvanted virosomal influenza (H5N1) vaccine compared to H5 naïve adults.

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.

Optimizing the time of day of influenza vaccine administration in adults aged 60-85 years: A randomized controlled trial

Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2

Influenza trials by city

Other conditions